by Öner Tulum, William Lazonick, Ken Jacobson, and Ellen Chappelka Nine months after the US Food and Drug Administration (FDA) granted emergency use authorization (EUA) to the first of…
Blog Series
#11. Help Wanted: Biomanufacturing workers needed for COVID-19 vaccines
by Ellen Chappelka, William Lazonick, and Ken Jacobson At the beginning of May 2021, it was reported that millions of doses of the Johnson & Johnson COVID…
#10. Scaling of COVID vaccine manufacturing: Dose selection, stability, and optimization of mRNA-based COVID vaccines
by Öner Tulum, William Lazonick, and Ken Jacobson This is the final installment of a three-part series on the scalability of mRNA vaccine production. The current article focuses…
#9. Scaling of COVID vaccine manufacturing: Procuring lipids and assembling lipid nanoparticles
by Öner Tulum, William Lazonick, and Ken Jacobson This is the second installment of a three-part series on the scalability of mRNA vaccine production. The current article focuses…
#8. Scaling of COVID vaccine manufacturing: It’s all about the lipids
by Öner Tulum, William Lazonick, and Ken Jacobson This is the first installment of a three-part series on the scalability of mRNA vaccine production. The current article focuses…
#7. Scaling of COVID vaccine manufacturing: What are the problems that can occur in the early stages?
by Öner Tulum, William Lazonick, and Ken Jacobson In March 2020, as a number of developers announced COVID-vaccine candidates that would begin clinical trials, vaccine manufacturers around the…
#6. Scaling of COVID vaccine manufacturing: Does the CEO understand the extraordinary complexities involved?
by Öner Tulum, William Lazonick, Ken Jacobson, and Ellen Chappelka During an interview on December 18, 2020, Moderna CEO Stéphane Bancel revealed his “Never Again Plan,” which…
#5. Scaling of COVID vaccine manufacturing: What manufacturing activities are involved and why are they so difficult?
by Öner Tulum, William Lazonick, and Ken Jacobson In March and April 2021, Americans received as many as four million doses a day of COVID-19 vaccines, far…
#4. Who are the CDMOs? For whom is their capacity being deployed to produce COVID vaccines?
by Öner Tulum, William Lazonick, and Ken Jacobson In responding to the COVID-19 pandemic, the global pharmaceutical industry has…
#3. Where do those COVID vaccines come from?
by Öner Tulum, William Lazonick, and Ken Jacobson The success of the worldwide COVID-vaccine rollout depends on decisions regarding the utilization of available production capacity made both independently…